Page last updated: 2024-12-08
alanopine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
alanopine: imino acid produced by a dehydrogenase found in the adductor muscle of the oyster, Crassostrea gigas; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
2,2'-iminodipropanoic acid : An amino dicarboxylic acid that is 2,2'-iminodiacetic acid substituted by methyl groups at positions 2 and 2'. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 439943 |
CHEBI ID | 857 |
SCHEMBL ID | 109878 |
MeSH ID | M0085969 |
Synonyms (20)
Synonym |
---|
CHEBI:857 |
2,2'-azanediyldipropanoic acid |
2,2'-iminodipropanoic acid |
C03210 |
alanopine |
73890-66-1 |
2,2'-iminodipropionic acid |
AKOS014776823 |
2-[(1-carboxyethyl)amino]propanoic acid |
l-alanine, n-(1-carboxyethyl)- (9ci) |
219755-19-8 |
SCHEMBL109878 |
(+/-)-form |
(+/-)-2,2'-iminobispropanoic acid |
n-(1-carboxyethyl)-l-alanine |
2,2'-iminobispropanoic acid |
CS-0239586 |
EN300-2156815 |
Q27105373 |
alanine, n-(1-carboxyethyl)- (9ci) |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
Class | Description |
---|---|
amino dicarboxylic acid | |
amino acid opine | Any opine whose structure is based on the condensation of an amino acid with a carbohydrate or a keto-acid. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (13)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 6 (46.15) | 18.7374 |
1990's | 2 (15.38) | 18.2507 |
2000's | 2 (15.38) | 29.6817 |
2010's | 3 (23.08) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 13 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |